Thursday, June 21, 2007

Multimechanism Drugs


Date: June 2007
Length: 00:4:26
Size: 2.02MB

Thought Leader:James S. Burns, President and CEO, EntreMed Inc.

Mr. Burns talks about the advantages of multimechanism drugs to solve distinct development challenges in the oncology arena, the complexities of drug development, and the challenges associated with running a biotechnology company.

Play Full Podcast

For more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.

No comments: